The preclinical data indicate that NGR-hTNF modifies the composition of the tumor microenvironment, including the infiltration of CD8+ T cells, and favors the secretion of cytokines and chemokines [55], thus suggesting that NGR-hTNF might enhance the efficacy of immune checkpoint inhibitors [56]. The gene discussed is RTN4R; the disease is neoplasm.